224 related articles for article (PubMed ID: 30526126)
41. Incorporation of GM-CSF or CD40L Enhances the Immunogenicity of Hantaan Virus-Like Particles.
Cheng LF; Wang F; Zhang L; Yu L; Ye W; Liu ZY; Ying QK; Wu XA; Xu ZK; Zhang FL
Front Cell Infect Microbiol; 2016; 6():185. PubMed ID: 28066721
[TBL] [Abstract][Full Text] [Related]
42. Pathogen-like particles: biomimetic vaccine carriers engineered at the nanoscale.
Rosenthal JA; Chen L; Baker JL; Putnam D; DeLisa MP
Curr Opin Biotechnol; 2014 Aug; 28():51-8. PubMed ID: 24832075
[TBL] [Abstract][Full Text] [Related]
43. Recombinant virus-like particles elicit protective immunity against avian influenza A(H7N9) virus infection in ferrets.
Liu YV; Massare MJ; Pearce MB; Sun X; Belser JA; Maines TR; Creager HM; Glenn GM; Pushko P; Smith GE; Tumpey TM
Vaccine; 2015 Apr; 33(18):2152-8. PubMed ID: 25772674
[TBL] [Abstract][Full Text] [Related]
44. Enveloped virus-like particle platforms: vaccines of the future?
Pitoiset F; Vazquez T; Bellier B
Expert Rev Vaccines; 2015 Jul; 14(7):913-5. PubMed ID: 25968245
[TBL] [Abstract][Full Text] [Related]
45. Plant-derived H7 VLP vaccine elicits protective immune response against H7N9 influenza virus in mice and ferrets.
Pillet S; Racine T; Nfon C; Di Lenardo TZ; Babiuk S; Ward BJ; Kobinger GP; Landry N
Vaccine; 2015 Nov; 33(46):6282-9. PubMed ID: 26432915
[TBL] [Abstract][Full Text] [Related]
46. Retrovirus-Based Virus-Like Particle Immunogenicity and Its Modulation by Toll-Like Receptor Activation.
Pitoiset F; Vazquez T; Levacher B; Nehar-Belaid D; Dérian N; Vigneron J; Klatzmann D; Bellier B
J Virol; 2017 Nov; 91(21):. PubMed ID: 28794025
[TBL] [Abstract][Full Text] [Related]
47. Platform for the generation of oral vaccines based on protozoan surface proteins.
Serradell MDC; Rupil LL; Luján HD
Medicina (B Aires); 2019; 79(Spec 6/1):559-563. PubMed ID: 31864226
[TBL] [Abstract][Full Text] [Related]
48. A virus-like particle vaccine confers protection against enterovirus D68 lethal challenge in mice.
Dai W; Zhang C; Zhang X; Xiong P; Liu Q; Gong S; Geng L; Zhou D; Huang Z
Vaccine; 2018 Jan; 36(5):653-659. PubMed ID: 29295756
[TBL] [Abstract][Full Text] [Related]
49. Virus-like Particle Vaccines and Platforms for Vaccine Development.
Kheirvari M; Liu H; Tumban E
Viruses; 2023 May; 15(5):. PubMed ID: 37243195
[TBL] [Abstract][Full Text] [Related]
50. Immunization with phage virus-like particles displaying Zika virus potential B-cell epitopes neutralizes Zika virus infection of monkey kidney cells.
Basu R; Zhai L; Contreras A; Tumban E
Vaccine; 2018 Feb; 36(10):1256-1264. PubMed ID: 29395533
[TBL] [Abstract][Full Text] [Related]
51. Effects of varying antigens and adjuvant systems on the immunogenicity and safety of investigational tetravalent human oncogenic papillomavirus vaccines: results from two randomized trials.
Van Damme P; Leroux-Roels G; Simon P; Foidart JM; Donders G; Hoppenbrouwers K; Levin M; Tibaldi F; Poncelet S; Moris P; Dessy F; Giannini SL; Descamps D; Dubin G
Vaccine; 2014 Jun; 32(29):3694-705. PubMed ID: 24674663
[TBL] [Abstract][Full Text] [Related]
52. Immunogenicity and protective efficacy of an EV71 virus-like particle vaccine against lethal challenge in newborn mice.
Sun S; Gao F; Mao Q; Shao J; Jiang L; Liu D; Wang Y; Yao X; Wu X; Sun B; Zhao D; Ma Y; Lu J; Kong W; Jiang C; Liang Z
Hum Vaccin Immunother; 2015; 11(10):2406-13. PubMed ID: 26036916
[TBL] [Abstract][Full Text] [Related]
53. Progress in developing virus-like particle influenza vaccines.
Quan FS; Lee YT; Kim KH; Kim MC; Kang SM
Expert Rev Vaccines; 2016 Oct; 15(10):1281-93. PubMed ID: 27058302
[TBL] [Abstract][Full Text] [Related]
54. A single intranasal administration of virus-like particle vaccine induces an efficient protection for mice against human respiratory syncytial virus.
Jiao YY; Fu YH; Yan YF; Hua Y; Ma Y; Zhang XJ; Song JD; Peng XL; Huang J; Hong T; He JS
Antiviral Res; 2017 Aug; 144():57-69. PubMed ID: 28529001
[TBL] [Abstract][Full Text] [Related]
55. Tetravalent recombinant dengue virus-like particles as potential vaccine candidates: immunological properties.
Liu Y; Zhou J; Yu Z; Fang D; Fu C; Zhu X; He Z; Yan H; Jiang L
BMC Microbiol; 2014 Dec; 14():233. PubMed ID: 25520151
[TBL] [Abstract][Full Text] [Related]
56. Development of a Novel Virus-Like Particle Vaccine Platform That Mimics the Immature Form of Alphavirus.
Urakami A; Sakurai A; Ishikawa M; Yap ML; Flores-Garcia Y; Haseda Y; Aoshi T; Zavala FP; Rossmann MG; Kuno S; Ueno R; Akahata W
Clin Vaccine Immunol; 2017 Jul; 24(7):. PubMed ID: 28515133
[TBL] [Abstract][Full Text] [Related]
57. Self-assembly of virus-like particles of rabbit hemorrhagic disease virus capsid protein expressed in Escherichia coli and their immunogenicity in rabbits.
Guo H; Zhu J; Tan Y; Li C; Chen Z; Sun S; Liu G
Antiviral Res; 2016 Jul; 131():85-91. PubMed ID: 27118636
[TBL] [Abstract][Full Text] [Related]
58. Influenza virosomes as vaccine adjuvant and carrier system.
Moser C; Müller M; Kaeser MD; Weydemann U; Amacker M
Expert Rev Vaccines; 2013 Jul; 12(7):779-91. PubMed ID: 23885823
[TBL] [Abstract][Full Text] [Related]
59. Human rotavirus virus-like particle vaccines evaluated in a neonatal gnotobiotic pig model of human rotavirus disease.
Azevedo MP; Vlasova AN; Saif LJ
Expert Rev Vaccines; 2013 Feb; 12(2):169-81. PubMed ID: 23414408
[TBL] [Abstract][Full Text] [Related]
60. Recombinant Modified Vaccinia Virus Ankara Generating Ebola Virus-Like Particles.
Schweneker M; Laimbacher AS; Zimmer G; Wagner S; Schraner EM; Wolferstätter M; Klingenberg M; Dirmeier U; Steigerwald R; Lauterbach H; Hochrein H; Chaplin P; Suter M; Hausmann J
J Virol; 2017 Jun; 91(11):. PubMed ID: 28331098
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
